| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | MED; EDM6; STL4; DJ149L1.1.2 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human COL9A1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于COL9A1抗体的3篇参考文献示例(内容基于真实研究归纳，但具体文献信息可能存在调整)：
---
1. **文献名称**: "Mutations in COL9A1 cause autosomal recessive Stickler syndrome"
**作者**: Baker S, et al.
**摘要**: 本研究通过全外显子测鉴发现COL9A1基因的隐性突变导致Stickler综合征。研究使用特异性COL9A1抗体进行免疫荧光和Western blot实验，验证突变导致蛋白表达异常，揭示了该基因在软骨发育中的作用。
2. **文献名称**: "Collagen IX deficiency leads to early-onset osteoarthritis in mice"
**作者**: Fässler R, et al.
**摘要**: 通过构建Col9a1基因敲除小鼠模型，利用COL9A1抗体进行组织染色和蛋白质分析，发现胶原IX缺失导致关节软骨结构破坏，为骨关节炎机制研究提供依据。
3. **文献名称**: "Antibody-based detection of COL9A1 in human intervertebral disc tissues"
**作者**: Wang H, et al.
**摘要**: 研究开发并验证了一种高特异性COL9A1多克隆抗体，通过免疫组化和ELISA技术检测人类椎间盘组织中COL9A1的表达水平，发现其与椎间盘退变程度呈负相关。
---
*注：以上文献为示例，实际引用需查询PubMed或相关数据库获取准确信息。如需具体文章，建议检索关键词“COL9A1 antibody” + “应用领域(如软骨、骨关节炎等)”。*
The COL9A1 antibody targets the alpha-1 chain of type IX collagen, a critical component of the extracellular matrix (ECM). Encoded by the COL9A1 gene, this chain combines with α2 and α3 chains (from COL9A2 and COL9A3) to form heterotrimeric type IX collagen, a fibril-associated collagen with interrupted triple helices (FACIT). This collagen type interacts with type II collagen in cartilage, stabilizing fibrillar networks and mediating ECM-cell signaling. COL9A1 is vital for maintaining structural integrity in articular cartilage, intervertebral discs, and other connective tissues.
Mutations in COL9A1 are linked to musculoskeletal disorders, including Stickler syndrome, multiple epiphyseal dysplasia (EDM2), and early-onset osteoarthritis. Antibodies against COL9A1 are used in research to study collagen assembly, tissue development, and disease mechanisms. They enable detection of COL9A1 expression and distribution via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Such studies help clarify how COL9A1 dysfunction contributes to ECM degradation in degenerative diseases. Additionally, these antibodies aid in diagnosing genetic collagenopathies by identifying abnormal protein expression in patient samples. Commercial COL9A1 antibodies are typically raised in rabbits or mice, with specificity validated in human, mouse, or rat tissues. Understanding COL9A1's role through antibody-based research supports therapeutic development targeting collagen-related pathologies.
×
